UBS Group Sets AstraZeneca PLC Price Target at £119 for 2023.
March 15, 2023
Trending News 🌥️
ASTRAZENECA ($LSE:AZN): UBS Group has set the share price target of AstraZeneca PLC at £119 for 2023. This is a significant milestone for the company, as it reflects the trust and confidence that the group has in the pharmaceutical giant. The new price target reflects UBS Group’s optimistic outlook for the future of AstraZeneca PLC, which is expected to continue investing in research and development and expanding its portfolio of innovative treatments. The share price target of £119 for 2023 is based on UBS Group’s opinion that AstraZeneca PLC will continue to remain a leader in the global pharmaceutical industry. The company has been at the forefront of innovation over the past several years and has developed some of the most successful treatments for a range of diseases. This includes treatments for cancer, diabetes, and respiratory diseases.
UBS Group’s deep dive analysis on AstraZeneca PLC’s operations and financials has led to the increased price target for 2023. The new share price target of £119 for 2023 is likely to draw interest from investors, who are looking to gain exposure to a reliable and profitable pharmaceutical company with a strong track record of success. AstraZeneca PLC’s share price is expected to rise as the company’s innovative treatments and robust pipeline of drugs are expected to drive future growth. With new treatments on the horizon and an experienced management team, AstraZeneca PLC is well-positioned to continue its success in the years ahead.
Price History
On Monday, AstraZeneca PLC (AZN) opened at £107.0 and closed at £106.9, down by 0.1% from its previous closing price of 107.0. This follows a positive media coverage, mainly regarding the company’s price target of £119 for 2023 set by UBS Group. This news has been well-received by investors and analysts alike, as it points to a bright future of the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Astrazeneca Plc. More…
| Total Revenues | Net Income | Net Margin |
| 44.35k | 3.29k | 7.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Astrazeneca Plc. More…
| Operations | Investing | Financing |
| 9.81k | -2.96k | -6.82k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Astrazeneca Plc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 96.48k | 59.42k | 23.9 |
Key Ratios Snapshot
Some of the financial key ratios for Astrazeneca Plc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 22.1% | 7.8% | 8.7% |
| FCF Margin | ROE | ROA |
| 16.3% | 6.7% | 2.5% |
Analysis
GoodWhale has conducted an analysis of ASTRAZENECA PLC‘s wellbeing, and our Risk Rating has determined that ASTRAZENECA PLC is a medium risk investment in terms of financial and business aspects. After further examination of ASTRAZENECA PLC’s income sheet, balance sheet and other aspects, we have detected two risk warnings. We urge those interested to thoroughly research the company before investing. For further details, please register on goodwhale.com to check it out. More…
Peers
AstraZeneca PLC is a pharmaceutical company that specializes in the development, manufacture, and marketing of prescription drugs. The company has a diversified product portfolio, which includes medications for cardiovascular, gastrointestinal, and respiratory diseases, as well as cancer. AstraZeneca PLC competes with Sanofi SA, Merck & Co Inc, and Pfizer Inc in the global pharmaceutical market.
– Sanofi SA ($OTCPK:SNYNF)
As of 2022, Sanofi SA has a market cap of 100.1B and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and is one of the world’s largest pharmaceutical companies. Sanofi is a diversified company, focused on human health. It covers seven areas: diabetes solutions, rare diseases, multiple sclerosis, oncology, immunology, vaccines and consumer healthcare.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co Inc is a pharmaceutical company with a market cap of 236.25B as of 2022. The company has a return on equity of 28.84%. The company produces a variety of drugs and vaccines for human and animal health.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a research-based pharmaceutical company with a market cap of 241.95B as of 2022. The company has a return on equity of 24.63%. Pfizer’s main focus is on the discovery, development, and commercialization of innovative therapeutics to treat patients with serious diseases. The company has a portfolio of products in various therapeutic areas, including cardiovascular, inflammation, immunology, oncology, pain, and rare diseases.
Summary
Investing in AstraZeneca PLC has been a viable option for investors as the company has seen positive media coverage and the UBS Group has set a price target of £119 per share for 2023. Investors have noted the company’s strong financial performance in recent years, including an increase in revenues and profits. The company has also undertaken a series of cost-saving measures to keep expenses low. AstraZeneca PLC’s share price has been consistently above its book value, reflecting its strong track record of profitability and growth.
With a wide range of products and services, the company is well-positioned to benefit from increased demand in the future. Analysts have also noted the company’s reliable dividend payments, making it an attractive option for income-seeking investors. As such, AstraZeneca PLC is a promising long-term investment.
